China Cord Blood Corporation releases financial results for second quarter and first half of fiscal year 2014

Published on November 7, 2013 at 7:18 AM · No Comments

China Cord Blood Corporation (NYSE: CO) (the "Company") today announced its plan to release financial results for the second quarter and first half of fiscal year 2014 on Thursday, November 14, 2013, after market close in the US. 

The Company will host a conference call at 8:00 a.m. ET on Friday, November 15, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 5266601. 

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the second quarter of fiscal 2014 earnings press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:00 p.m. ET on Thursday, November 14, 2013 and in the Company's Report on Form 6-K for the month of November 2013 available on the Securities and Exchange Commission's website at www.sec.gov.  

Posted in: Business / Finance

Tags: , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Researchers develop GI microbiome modulators to treat prediabetes and diabetes